Navigation Links
Codexis Reports Second Quarter 2011 Results

REDWOOD CITY, Calif., July 28, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced introduction of the CodeXol™ detergent alcohol product line, and announced financial results for the second quarter ended June 30, 2011.

CodeXol™ Detergent Alcohols:Detergent alcohols - a $6 billion worldwide market – are used to make surfactants which act as cleaning and emulsifying agents in household products. They are widely used in laundry detergents, shampoos and other consumer products.  Detergent alcohols today are made from non-sustainable palm kernel and petroleum sources.  CodeXol™ detergent alcohols will be produced from sustainable sources.

“We look forward to introducing the CodeXol™ line of detergent alcohols to the household and consumer products markets,” said Alan Shaw, Ph.D., President and Chief Executive Officer.   “Major consumer products companies are actively seeking more sustainable raw materials for their products in order to reduce environmental impact and minimize volatility in their supply chains.  Detergent alcohols can be made from sugar and, ultimately, sustainable cellulosic biomass.  Our proprietary cellulase enzymes, along with the detergent alcohols collaboration with Chemtex that we also announced today, represent important steps toward addressing this growing market need.”  

The CodeXol™ product line, a family of detergent alcohols that is under development, is enabled by Codexis’ proprietary CodeEvolver™ directed evolution technology.

Second Quarter Financial Highlights:Revenue: For the second quarter of 2011, the company reported revenues of $26.1 million, an increase of 6% from $24.5 million in the second quarter of 2010.  Product revenue of $8.4 million decreased 1% over the same time period primarily due to the timing of product orders.  Collaborative R&D revenue of $2.5 million increased 198% from $0.9 million in the second quarter of 2010, driven mainly by funded research for our carbon capture program.

Operating Expenses:  Research and development expenses in the second quarter of 2011 were $15.0 million, compared to $13.0 million for the second quarter of 2010.  The increase was primarily due to an increase in amortization related to intellectual property purchased from Maxygen, Inc. and stock compensation expenses. Selling, general and administrative expenses in the second quarter of 2011 increased to $9.3 million compared to $8.7 million over the same period of 2010, driven by higher stock compensation expense and higher compensation expense due to headcount increases.

Net Loss:  Net loss was ($5.0) million, or ($0.14) per share, based on 35.7 million weighted average common shares outstanding in the second quarter of 2011.   This compares to a net loss of ($3.9) million or ($0.15) per share during the second quarter of 2010.  

Adjusted EBITDA:  On a non-GAAP basis, Adjusted EBITDA decreased from $0.5 million in the second quarter of 2010 to $67,000 in 2011. Adjusted EBITDA is calculated by adjusting net loss for net interest expense, income taxes, depreciation, amortization, stock-based compensation and preferred stock warrant fair market valuation.  A reconciliation of net loss to Adjusted EBITDA is presented below.

Cash:  Cash, cash equivalents and marketable securities at June 30, 2011, decreased to $72.4 million compared to $82.0 million at March 31, 2011.  The company used ($0.3) million in cash from operations in the second quarter.

OutlookCodexis’ statements with regard to its outlook are based on current expectations. The following statements are forward looking, and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.

For the full year 2011, Codexis reaffirms its prior guidance and forecasts revenues of $120 million or greater, which would represent growth of 12% or greater compared to 2010. Codexis expects 2011 Adjusted EBITDA will be $5 million or greater.

Recent Developments

  • Codexis announced today a broad collaboration with Chemtex, a wholly-owned company of Italy’s Gruppo Mossi & Ghisolfi (“M&G Group”), to develop and produce sustainable detergent alcohols for use in the household products market.  The collaboration includes development of second generation detergent alcohols from cellulosic (non-food) biomass.  The collaboration combines Chemtex’s efficient pretreatment technology with Codexis’ high performance enzymes and fermentation process to convert a wide variety of feedstocks into detergent alcohols.  The parties expect that the production process will initially be piloted at Chemtex’s R&D facility in Rivalta, Italy.  Larger scale demonstrations are anticipated at Chemtex’s 40,000 metric ton per year cellulosic ethanol plant in Crescentino, Italy that is expected to be operational in 2012.  Chemtex will provide engineering services for the design and construction of Codexis commercial facilities for the production of detergent alcohols.  Codexis will market products resulting from the collaboration.
  • Codexis announced today that Pedro I. Mizutani, Executive Vice President in charge of upstream business at Raizen Energia Participacoes S.A., had been elected to the Codexis Board of  Directors effective July 15, 2011.   Mr. Mizutani serves as the Board representative of  Raizen, a biofuels joint venture between Shell and Cosan and Codexis’ largest stockholder.  Raizen is Brazil’s largest sugar and ethanol producer.  Prior to joining Raizen, Mr. Mizutani served as CEO of Cosan Sugar and Ethanol.  On June 2, Codexis announced that Equilon Enterprises LLC, a wholly owned subsidiary of Royal Dutch Shell plc, had completed the transfer of approximately 5.6 million shares of Codexis common stock to Raizen.  This transfer occurred as part of the closing of the joint venture.
  • Codexis announced on July 12, 2011 that it had successfully completed a 20,000 liter scale up of the company's proprietary cellulase enzymes. This scale up is an important  milestone for Codexis as it continues to move toward commercializing these enzymes.  Codexis’ cellulase enzymes may be used to convert non-food biomass to fermentable sugars, and ultimately to sustainable products including biofuels and bio-based performance ingredients in household goods such as laundry detergents and shampoos.  
  • Codexis and Shell have a research and development collaboration agreement that is focused on the development of advanced biofuels.  Consistent with its increasing focus on cellulosic ethanol, Shell has decided to shift resources out of the diesel fuel program and into the cellulosic ethanol program.  As part of this resource re-allocation, Shell will reduce the number of funded Codexis full-time equivalents, or FTEs, from 128 to 116 effective mid-August 2011, at which point 8 additional FTEs will move to the cellulosic ethanol program funded by Shell.  

  • Conference CallCodexis will hold a conference call for investors on July 28, 2011 at 1:30 p.m. PT (4:30 p.m. ET). The conference call dial-in numbers are US: 866-788-0541 or International: 857-350-1679, access code 54501345. A live webcast of the call will also be available from the Investor Relations section of A recording of the call will be available by calling US: 888-286-8010 or International: 617-801-6888, access code 93136720 beginning approximately two hours after the call, and will be available for up to thirty days. A webcast replay from today’s call will also be available from the Investor Relations section of approximately two hours after the call and will be available for up to thirty days.

    About Codexis, Inc.Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis’ technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell, carbon capture and biobased chemicals.  Wastewater treatment is a potential future market.

    Forward-Looking StatementsThis press release contains forward-looking statements relating to the company’s ability to develop and commercialize its CodeXol™ line of detergent alcohols, the company’s forecast for 2011 revenue and Adjusted EBITDA, the ability of Codexis and Chemtex to develop and commercialize detergent alcohols from a wide variety of feedstocks,  the company’s ability to develop and produce cellulase enzymes at commercial scale,  and funding and staffing on our Shell biofuels research collaboration.  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results can be found in Codexis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2011, including under the caption “Risk Factors.”  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.Codexis, Inc.Condensed Consolidated Statements of Operations(Unaudited)(In Thousands, Except Per Share Amounts)Three Months EndedSix Months EndedJune 30,June 30,20112010% change20112010% changeRevenues:Product$  8,397$  8,484-1%$ 21,329$ 14,76045%Related party collaborative research and development14,84714,6531%29,67030,695-3%Collaborative research and development2,538851198%5,2011,511244%Government grants273492-45%8893,214-72%Total revenues 26,05524,4806%57,08950,18014%Costs and operating expenses: Cost of product revenues7,1066,07517%18,75611,29366%Gross margin $1,2912,4092,5733,467Gross margin %15%28%12%23%Research and development14,96513,00415%28,71525,98611%Selling, general and administrative9,2768,6527%18,28917,2526%Total costs and operating expenses31,34727,73113%65,76054,53121%Loss from operations (5,292)(3,251)63%(8,671)(4,351)99%Interest income714654%1207462%Interest expense and other, net16(654)nm34(1,012)nmLoss before provision (benefit) for income taxes (5,205)(3,859)35%(8,517)(5,289)61%Provision (benefit) for income taxes (165)87nm(6)26nmNet loss$ (5,040)$ (3,946)28%$ (8,511)$ (5,315)60%Net loss per share of common stock,basic and diluted$   (0.14)$   (0.15)$   (0.24)$   (0.36)Weighted average common shares used in computing net loss per share of common stock, basic and diluted35,68526,55735,40214,701Codexis, Inc.Condensed Consolidated Balance Sheets(Unaudited)(In Thousands)June 30,December 31,20112010AssetsCurrent assets:   Cash and cash equivalents $   32,082$
    72,396   Marketable securities14,593-   Accounts receivable, net 11,30610,620   Related party accounts receivable-4,713   Inventories 4,1872,817   Prepaid expenses and other current assets2,3801,646Total current assets 64,54892,192Restricted cash1,5121,466Non-current marketable securities25,7691,650Property and equipment, net 21,61121,452Intangible assets, net 18,30120,158Goodwill3,2413,241Other non-current assets 1,1531,141Total assets $ 136,135$
    41,300Liabilities and stockholders' equityCurrent liabilities:   Accounts payable $
    9,208   Accrued compensation5,0198,107   Other accrued liabilities 7,4065,630   Deferred revenues 386455   Related party deferred revenues4,0844,084Total current liabilities 24,60927,484Deferred revenues, net of current portion1,5791,671Related party deferred revenues, net of current portion1,3613,403Other long-term liabilities 1,8001,381Total  liabilities 29,34933,939Stockholders' equity:Common stock44Additional paid-in capital283,028275,540Accumulated other comprehensive loss415(34)Accumulated deficit(176,661)(168,149)Total  stockholders' equity106,786107,361Total liabilities, and stockholders' equity$ 136,135$
    41,300Codexis, Inc.Condensed Consolidated Statements of Cash Flow(Unaudited)(In Thousands)Six Months EndedJune 30,20112010Operating activities:Net loss$ (8,511)$   (5,315)Adjustments to reconcile net loss to net cash used in operating activities:Amortization of intangible assets1,858302Depreciation and amortization of property and equipment3,7603,438Revaluation of redeemable convertible preferred stock warrant liability-677Loss (gain) on disposal of property and equipment59-Gain from extinguishment of asset retirement obligation(124)-Stock-based compensation4,8563,951Accretion of asset retirement obligation29-Amortization of debt discount-104Accretion (amortization) of premium/discount on marketable securities51183Changes in operating assets and liabilities:Accounts receivable4,027(42)Inventories(1,370)739Prepaid expenses and other current assets(735)(3,126)Other assets(13)2,395Accounts payable(1,493)(1,413)Accrued compensation(3,088)(1,477)Related party payable-(1,046)Other accrued liabilities2,554(5,133)Deferred revenues(2,203)(12,950)Net cash provided by (used in) operating activities(343)(18,713)Investing activities:(Increase) decrease  in restricted cash(46)65Purchase of property and equipment(4,187)(3,192)Purchase of marketable securities(38,152)(49,051)Proceeds from sale of marketable securities-1,605Proceeds from maturities of marketable securities-21,960Net cash provided by (used in) investing activities(42,385)(28,613)Financing activities:Principal payments on financing obligations-(2,681)Payments in preparation for initial public offering-(3,106)Proceeds from issuance of common stock on IPO, net of underwriting discounts-72,539Proceeds from exercises of stock options2,390254Net cash provided by (used in) financing activities2,39067,006Effect of exchange rate changes on cash and cash equivalents24(52)Net increase in cash and cash equivalents(40,314)19,628Cash and cash equivalents:   Beginning of the period72,39631,785   End of the period32,08251,413   Marketable securities at the end of period40,36248,894Cash, cash equivalents and marketable securities$ 72,444$ 100,307Reconciliation of GAAP to Non-GAAP Financial InformationIn this press release, in addition to GAAP financial results, we present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA to evaluate the effectiveness of our business strategies.  

    A reconciliation of GAAP net loss to Adjusted EBITDA is included in the table below.

    Codexis, Inc.Reconciliation of GAAP Net Loss to Adjusted EBITDA(Unaudited)(In Thousands)Three Months EndedSix Months EndedJune 30,June 30,Calculation of Adjusted EBITDA2011201020112010Net loss

    (5,040)$   (3,946)$
    (5,315)Adjustments:Minus: Interest income


    (120)(74)Plus: Interest expense

    -96-394Plus: Income taxes

    (165)87(6)26Plus: Depreciation and amortization

    2,7941,8845,6183,740Plus: Stock-based compensation

    2,5492,1714,8353,885Plus: Preferred stock warrant fair market valuation adjustment

    -281-677   Adjusted EBITDA$
    3,333Adjusted EBITDA has limitations as an analytical tool. Some of these limitations are:

  • Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
  • Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements; and
  • Non-cash compensation is and will remain a key element of our overall long-term incentive compensation package, although we exclude it as an expense when evaluating our ongoing operating performance for a particular period.

  • Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally.

    Contacts: Investors:   Henk Adriaenssens,, 650-421-8331
    Media: Lyn Christenson,, 650-421-8144 or Saskia Sidenfaden,, 212-827-3771.


    SOURCE Codexis, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market
    2. Codexis to Present at the Pacific Crest and Canaccord Genuity Conferences
    3. Codexis to Present at 3 Investor Conferences in June
    4. Codexis Achieves Development Milestones With Teva
    5. Codexis to Present at Barclays Conference
    6. Codexis to Announce First Quarter 2011 Financial Results on May 5, 2011
    7. Codexis Names Jacques Beaudry-Losique VP Corporate Development & Strategy
    8. Codexis Announces Carbon Capture Progress at ARPA-E Summit
    9. Codexis Names David Anton CTO & SVP, Process Development & Manufacturing
    10. Codexis to Present at the Jefferies and Pacific Crest Conferences
    11. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
    Post Your Comments:
    (Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
    (Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
    (Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
    (Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
    (Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
    (Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
    Breaking Medicine News(10 mins):